BR112018075371A2 - usos terapêuticos de um inibidor de c-raf - Google Patents
usos terapêuticos de um inibidor de c-rafInfo
- Publication number
- BR112018075371A2 BR112018075371A2 BR112018075371-8A BR112018075371A BR112018075371A2 BR 112018075371 A2 BR112018075371 A2 BR 112018075371A2 BR 112018075371 A BR112018075371 A BR 112018075371A BR 112018075371 A2 BR112018075371 A2 BR 112018075371A2
- Authority
- BR
- Brazil
- Prior art keywords
- relates
- present
- combination
- raf
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente invenção refere-se ao uso de um inibidor de c-raf para uso no tratamento de uma doença proliferativa, particularmente um tumor sólido que abriga proteína cinase ativada por mitógeno (mapk). a presente invenção refere-se também a uma combinação farmacêutica que compreende (a) pelo menos uma molécula de anticorpo (por exemplo, moléculas de anticorpo humanizadas) que se ligam à morte programada 1 (pd-1) e (b) um inibidor de c-raf ou seu sal farmaceuticamente aceitável. a presente invenção refere-se também a uma tal combinação para administração simultânea, separada ou sequencial para o tratamento de uma doença proliferativa, particularmente um tumor sólido que abriga alteração de proteína cinase ativada por mitógeno (mapk) e um pacote comercial compreendendo uma tal combinação.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348720P | 2016-06-10 | 2016-06-10 | |
| US62/348,720 | 2016-06-10 | ||
| PCT/IB2017/053405 WO2017212442A1 (en) | 2016-06-10 | 2017-06-08 | Therapeutic uses of a c-raf inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018075371A2 true BR112018075371A2 (pt) | 2019-03-19 |
Family
ID=59215827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018075371-8A BR112018075371A2 (pt) | 2016-06-10 | 2017-06-08 | usos terapêuticos de um inibidor de c-raf |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190175609A1 (pt) |
| EP (1) | EP3468595A1 (pt) |
| JP (1) | JP2019517549A (pt) |
| KR (1) | KR20190017767A (pt) |
| CN (1) | CN109310761A (pt) |
| AU (1) | AU2017279046B2 (pt) |
| BR (1) | BR112018075371A2 (pt) |
| CA (1) | CA3026876A1 (pt) |
| CL (1) | CL2018003530A1 (pt) |
| IL (1) | IL262961A (pt) |
| MX (1) | MX2018015353A (pt) |
| RU (1) | RU2018146886A (pt) |
| WO (1) | WO2017212442A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102341660B1 (ko) * | 2016-09-19 | 2021-12-23 | 노파르티스 아게 | Raf 억제제 및 erk 억제제를 포함하는 치료적 조합 |
| KR20210137508A (ko) | 2019-03-08 | 2021-11-17 | 아우리스 헬스, 인코포레이티드 | 의료 시스템 및 응용을 위한 틸트 메커니즘 |
| CN114746417B (zh) * | 2019-12-06 | 2023-12-08 | 齐鲁制药有限公司 | Pan-RAF激酶抑制剂的联芳基化合物 |
| CN113912591B (zh) * | 2020-07-08 | 2023-10-20 | 齐鲁制药有限公司 | 联芳基化合物 |
| WO2022253334A1 (zh) * | 2021-06-04 | 2022-12-08 | 南京明德新药研发有限公司 | 一种raf激酶抑制剂的晶型及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR090151A1 (es) * | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| US9242969B2 (en) * | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| SG11201605824XA (en) * | 2014-02-04 | 2016-08-30 | Pfizer | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer |
| JP6673896B2 (ja) * | 2014-07-15 | 2020-03-25 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及びｍｅｋ阻害剤を使用した癌を処置するための組成物 |
-
2017
- 2017-06-08 RU RU2018146886A patent/RU2018146886A/ru not_active Application Discontinuation
- 2017-06-08 CA CA3026876A patent/CA3026876A1/en not_active Abandoned
- 2017-06-08 MX MX2018015353A patent/MX2018015353A/es unknown
- 2017-06-08 CN CN201780035192.1A patent/CN109310761A/zh active Pending
- 2017-06-08 WO PCT/IB2017/053405 patent/WO2017212442A1/en unknown
- 2017-06-08 AU AU2017279046A patent/AU2017279046B2/en not_active Ceased
- 2017-06-08 JP JP2018564296A patent/JP2019517549A/ja active Pending
- 2017-06-08 US US16/307,920 patent/US20190175609A1/en not_active Abandoned
- 2017-06-08 KR KR1020187035219A patent/KR20190017767A/ko not_active Application Discontinuation
- 2017-06-08 EP EP17733028.9A patent/EP3468595A1/en not_active Withdrawn
- 2017-06-08 BR BR112018075371-8A patent/BR112018075371A2/pt not_active Application Discontinuation
-
2018
- 2018-11-12 IL IL262961A patent/IL262961A/en unknown
- 2018-12-07 CL CL2018003530A patent/CL2018003530A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017279046B2 (en) | 2020-07-02 |
| KR20190017767A (ko) | 2019-02-20 |
| IL262961A (en) | 2018-12-31 |
| RU2018146886A3 (pt) | 2020-10-15 |
| CN109310761A (zh) | 2019-02-05 |
| RU2018146886A (ru) | 2020-07-10 |
| US20190175609A1 (en) | 2019-06-13 |
| JP2019517549A (ja) | 2019-06-24 |
| AU2017279046A1 (en) | 2018-12-06 |
| MX2018015353A (es) | 2019-09-09 |
| CL2018003530A1 (es) | 2019-02-15 |
| EP3468595A1 (en) | 2019-04-17 |
| WO2017212442A1 (en) | 2017-12-14 |
| CA3026876A1 (en) | 2017-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018075371A2 (pt) | usos terapêuticos de um inibidor de c-raf | |
| BR112019005046A2 (pt) | combinações terapêuticas compreendendo um inibidor de raf e um inibidor de erk | |
| EA201792273A1 (ru) | Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела | |
| CY1124791T1 (el) | Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων | |
| BR112018077457A2 (pt) | composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado | |
| BR112019001818A2 (pt) | terapia combinada para câncer | |
| BR112016012506A8 (pt) | combinações farmacêuticas, seus usos, e uso de um portador de dados | |
| AR104812A1 (es) | Combinaciones terapéuticas y métodos para tratar neoplasias | |
| DOP2016000133A (es) | Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este | |
| BR112018008918A2 (pt) | compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos | |
| BR112018009064A2 (pt) | anticorpo de pd-l1, fragmento de ligação ao antígeno do mesmo e aplicação médica do mesmo | |
| BR112017017078A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para prevenir, gerenciar, tratar ou amenizar uma doença. | |
| BR112017027778A2 (pt) | anticorpos para o fator xi e métodos de uso | |
| EA201790674A1 (ru) | Индуцирующий цитотоксичность терапевтический агент | |
| BR112017006468A2 (pt) | anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer | |
| CL2019003091A1 (es) | Terapia de combinación. | |
| BR112019003989A2 (pt) | métodos de utilização de um anticorpo biespecífico que reconhece o fator de coagulação ix e/ou o fator de coagulação ix ativado e o fator de coagulação x e/ou o fator de coagulação x ativado | |
| WO2017106810A3 (en) | Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof | |
| CO2019009586A2 (es) | Anticuerpos anti-gitr y métodos de uso de los mismos | |
| CL2019003032A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. | |
| BR112018002427A8 (pt) | Uso de alvocidib e de azacitidina ou decitabina para tratar câncer e kit e composição farmacêutica contendo as ditas substâncias | |
| BR112021015036A2 (pt) | Tratamento para câncer com imunoconjugados do anticorpo ror1 | |
| BR112021008582A8 (pt) | Regime de dosagem de anticorpo anti-tigit para tratamento de câncer | |
| BR112022008365A2 (pt) | Inibidores de cd73 | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |